VEGFR1/VEGFR2 derived epitope peptide pancreatic vaccine (Tokyo University)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameVEGFR1/VEGFR2 derived epitope peptide pancreatic vaccine (Tokyo University)

Drug Alias Nameangiogenic peptide vaccine (Tokyo University)

ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionVascular endothelial growth factor receptor 1 agonistsVascular endothelial growth factor receptor 2 agonists

TargetsVascular endothelial growth factor receptor 2Vascular endothelial growth factor receptor 1

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Tokyo

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of Tokyo

Active IndicationsN/A

Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A